FCMI
SYRS

Foresite Capital Management III’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Foresite Capital Management III’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,000
Closed -$832K – 22
2016
Q3 		$832K Sell
6,000
-9,000
-60% -$1.14M 0.39% 16
2016
Q2 		$2.72M Buy
+15,000
New +$2.72M 1.87% 11

Other funds holding SYRS

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Foresite Capital Management III's SYRS Position: Q4 2016 in Review

Foresite Capital Management III sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2016, closing a stake of 6,000 shares — an estimated $832K sold.

Foresite Capital Management III first reported a position in SYRS in Q2 2016 and held it in 2 quarters. The position peaked at $2.72M in Q2 2016. 42 funds tracked by Wall St. Rank hold SYRS as of Q4 2016.

  • Foresite Capital Management III reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 6,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2016, an estimated $832K.
  • Foresite Capital Management III first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • Foresite Capital Management III's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.72M in Q2 2016.
  • 42 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2016.

Based on Foresite Capital Management III's 13F filing for Q4 2016, filed 10 Feb 2017.